Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluticasone propionate controlled release - Eupraxia Pharmaceuticals

Next Previous
Drug Profile

Fluticasone propionate controlled release - Eupraxia Pharmaceuticals

Alternative Names: EP 104IAR; EP-104; EP-104GI; Fluticasone propionate - Eupraxia

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eupraxia Pharmaceuticals
  • Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Inorganic sulfur compounds; Small molecules; Steroids
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pain
  • Phase I/II Eosinophilic oesophagitis

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Pain(In the elderly, In adults) in Canada (Intra-articular, Injection)
  • 06 May 2025 Efficacy data from a phase Ib/IIa trial in Eosinophilic esophagitis released by Eupraxia Pharmaceuticals
  • 06 May 2025 Aadverse events data from a phase Ib/IIa trial in Eosinophilic esophagitis released by Eupraxia Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top